NKGen Biotech Inc (NKGN)
1.20
+0.01
(+0.84%)
USD |
NASDAQ |
Jun 24, 16:00
1.20
0.00 (0.00%)
After-Hours: 20:00
NKGen Biotech Enterprise Value: 51.79M for June 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 21, 2024 | 51.79M |
| June 20, 2024 | 51.54M |
| June 18, 2024 | 51.29M |
| June 17, 2024 | 53.78M |
| June 14, 2024 | 55.28M |
| June 13, 2024 | 54.53M |
| June 12, 2024 | 53.78M |
| June 11, 2024 | 56.77M |
| June 10, 2024 | 57.27M |
| June 07, 2024 | 57.77M |
| June 06, 2024 | 55.77M |
| June 05, 2024 | 57.77M |
| June 04, 2024 | 57.52M |
| June 03, 2024 | 60.50M |
| May 31, 2024 | 63.24M |
| May 30, 2024 | 60.75M |
| May 29, 2024 | 62.49M |
| May 28, 2024 | 59.01M |
| May 24, 2024 | 57.02M |
| May 23, 2024 | 67.97M |
| May 22, 2024 | 65.98M |
| May 21, 2024 | 65.48M |
| May 20, 2024 | 64.24M |
| May 17, 2024 | 49.55M |
| May 16, 2024 | 49.80M |
| Date | Value |
|---|---|
| May 15, 2024 | 50.05M |
| May 14, 2024 | 50.05M |
| May 13, 2024 | 52.54M |
| May 10, 2024 | 50.02M |
| May 09, 2024 | 49.80M |
| May 08, 2024 | 52.05M |
| May 07, 2024 | 50.70M |
| May 06, 2024 | 51.82M |
| May 03, 2024 | 53.85M |
| May 02, 2024 | 51.37M |
| May 01, 2024 | 54.52M |
| April 30, 2024 | 55.64M |
| April 29, 2024 | 58.57M |
| April 26, 2024 | 58.40M |
| April 25, 2024 | 66.83M |
| April 24, 2024 | 60.68M |
| April 23, 2024 | 63.87M |
| April 22, 2024 | 55.20M |
| April 19, 2024 | 46.90M |
| April 18, 2024 | 41.29M |
| April 17, 2024 | 45.17M |
| April 16, 2024 | 49.27M |
| April 15, 2024 | 49.44M |
| April 12, 2024 | 48.54M |
| April 11, 2024 | 50.34M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
37.34M
Minimum
Feb 29 2024
136.14M
Maximum
Oct 02 2023
66.63M
Average
66.14M
Median
Enterprise Value Benchmarks
| Bio-Path Holdings Inc | 3.323M |
| GT Biopharma Inc | -5.768M |
| Palisade Bio Inc | -6.879M |
| Flora Growth Corp | 11.43M |
| ProKidney Corp | 1.433B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.382M |
| Total Expenses (Quarterly) | 7.621M |
| EPS Diluted (Quarterly) | -0.25 |
| Earnings Yield | -388.8% |